With 164+ beds in its state-of-the-art CRUs and thought-leader expertise in the design and execution of complex Phase I-IIa trials, Apex Innovative Sciences offers unique capabilities to accelerate and de-risk drug development early in the process. Apex’s trial site organizations, Collaborative Neuroscience Research (CNS) and Hassman Research Institute (HRI), have harmonized clinical, operational, and scientific processes across sites, including standardized biomarkers, disease models, imaging, and electrophysiologic assessments, enabling the seamless execution of trials with the enrollment benefits of bi-coastal operations.
Download the Apex fact sheet.
Larry Ereshefsky, Pharm.D.
Chief Scientific Officer
Dr. Ereshefsky is an internationally recognized key opinion leader in clinical translational central nervous system research with a proven track record in designing a wide variety of Phase I-IIa studies. He is a leader in the application of translational drug development tools, and in the use of signal detection strategies to minimize placebo response. He is a retired Regents Professor of Pharmacy, Psychiatry, and Pharmacology from The University of Texas/UT Health Science Center. Subsequently, he was the VP, Principal Clinical Pharmacologist, and Global CNS Leader for Early Phase at PAREXEL. Dr. Ereshefsky has published more than 130 peer-reviewed scholarly articles and abstracts.
David Walling, Ph.D.
Chief Clinical Officer, Apex
CEO and Principal Investigator, CNS
Dr. Walling, a licensed clinical psychologist, has served as an investigator in over 400 trials, including over 100 Phase I trials. He is a highly sought after KOL in psychiatry and cognition as well as digital device and software technologies. He has extensive experience advising leading pharmaceutical sponsors in many ways including the creation of drug development plans, design and analysis of clinical trials, and preparation for interactions with regulatory agencies. He has authored dozens of articles on psychiatric indications that have been published in leading scientific journals, and also provides training to rater training companies for some of the most widely used psychiatric and cognitive rating scales.
Howard Hassman, D.O., AOBFP
Chief Executive Officer, Apex
CEO and Principal Investigator, HRI
Dr. Hassman, a board-certified family practitioner, has served as an investigator in almost 400 trials, including a wide range of early drug development trials from First-in-Human through Proof-of-concept. He is considered an expert in the field of Psychopharmacology, and has an extensive background in psychodynamic psychotherapy, pain management, and addiction medicine. He provides a broad range of expert consulting services to clients for early drug development, developing creative, de-risked solutions for a variety of clinical programs. Dr. Hassman holds multiple advisory board memberships and has authored numerous articles that have been published in leading scientific journals.
CNS operates outpatient clinics in Long Beach, Garden Grove, and Torrance, CA. The Long Beach location oﬀers a state-of-the-art inpatient unit with 60 beds as well as a 16-bed Asian Bridging Studies unit.
HRI has inpatient and outpatient facilities in both Marlton and Berlin, NJ. The state-of-the-art inpatient unit in Marlton has 60 beds, and the inpatient unit on the Berlin campus has 28 beds.
Knowledge & Experience
Our KOLs have supported pharma with:
- Clinical drug development planning
- Clinical trials methodologies
- PK/PD modeling
- Experimental medicine strategies
- Development, validation, and application of biomarkers
- Vendor selection (Imaging, Electrophysiologic, cognitive sciences)
- First-In-Human (FIH), Single ascending dose (SAD) and Multiple ascending dose (MAD)
- Translational and experimental medicine studies
- Adaptive and umbrella designs
- Elderly and patient populations
- Asian sensitivity and bridging in Japanese, Chinese, and Korean first-generation subjects
- PK/PD relationships with QEEG/ERP, fMRI/PET
- QTc, TQTc, cardiac monitoring
- 505(b)(2) program strategies
- Biologics and biosimilars
- Bioequivalence/Drug-Drug Interaction (DDI)/Food Effect
- Digital device and software technologies
- Orphan indications
- Imaging – PET, MRI, fMRI, MRS, MRE, FibroScan
- Electrophysiology – EEG, PSG, and QEEG / ERP
- Pain models in HNVs and patients
- Digital Therapies – health devices, software, and applications
- Safety – capnography, pulse ox, continuous safety EEGs, telemetry, biomarkers
- Cognitive and behavioral assessments, including impairment of function
- Driving Simulators
- CSF collection
- Healthy Volunteers: Including sub-populations of Asian, elderly, post-menopausal females, tobacco users
- Psychiatry: ADHD, Anxiety, Bipolar, Depression, PTSD, Schizophrenia
- Neurology: Alzheimer’s, Multiple Sclerosis, Parkinson’s, Post-Stroke, Sleep Disorders
- Pain: Acute/Chronic, Fibromyalgia, Osteoarthritis, Migraine, Pain models such as UV and capsaicin
- Human Abuse Liability: Addictions, Exploratory assessments, Definitive HAL testing
- Asian Studies: Bridging to Japanese, Chinese, and other Asian populations
- Impairment: Cognitive Dysfunction, Validated Driving Simulation studies
- Internal Medicine: Endocrinology, Gastrointestinal, Immunology, Pulmonology, NASH/NAFLD, and more
- Dermatology: Alopecia, Psoriasis, Acne, Atopic Dermatitis, Rosacea, Aesthetics
For more information or to further discuss your study needs please contact:
Bobbie Theodore, M.S.